Merger Terms Include Funding for Combined Company and Other Aspects
of the Merger Disclosed in the Proxy/Prospectus
Jaguar to Host Conference Call Friday, July 28th at 8:30 a.m. Eastern
Time
SAN FRANCISCO--(BUSINESS WIRE)--Jul. 27, 2017--
Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar) and Napo
Pharmaceuticals, Inc. (Napo) announced that at separate special
stockholder meetings today the stockholders of both companies approved
proposals recommended by the Jaguar and Napo boards regarding the merger
of Jaguar and Napo.
The merger transaction remains on track to become effective on Monday,
July 31, 2017, at which point Jaguar’s name will be changed to Jaguar
Health, Inc., and Napo will operate as a wholly-owned subsidiary of
Jaguar focused on human health and the ongoing commercialization of
Mytesi®, which is approved by the U.S. FDA for the
symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on
antiretroviral therapy. As previously announced, the terms of the merger
include funding for the combined company and for other aspects of the
merger as disclosed in the definitive joint proxy statement/prospectus.
“Today’s votes represent a pivotal development in the evolution of both
companies. It is truly transformational for Jaguar Health to
forward-integrate into an important revenue stream from Mytesi®,
for which the company will hold unencumbered global rights and is
pursuing multiple follow-on indications for various chronic
gastrointestinal disorders. This merger speaks to the shared vision and
persistence of the dedicated and talented team members at both Jaguar
and Napo—some of whom have worked for more than 20 years to change the
standard of care for gastrointestinal disease in humans and animals,”
stated Lisa Conte, Jaguar's president and CEO and Napo’s interim CEO.
“We are grateful for the continued enthusiasm and support for this
merger, and we remain excited about the opportunity we believe this
combination will create for our stockholders as well as Mytesi®
patients and animals.”
Conference Call
The Jaguar management team will host a call on Friday, July 28, 2017 at
8:30 a.m. Eastern Time to discuss the merger. Investors interested in
listening to the live call should dial 877-627-6544 (Toll Free),
719-325-4888 (International). Please ask the operator to connect you to
the call or provide the conference ID number: 4112552. A live webcast of
the conference call will be available online which can be accessed on
the investor relations section of the Jaguar website (click
here). Please allow extra time prior to the call to visit the site
and download any necessary software to listen to the live broadcast.
For interested individuals unable to join the conference call, a replay
of the webcast will be available on the investor relations section of
Jaguar’s website (click
here) for 90 days following the call. Also, a dial-in replay of the
call will be available through August 4, 2017, at 844-512-2921 (U.S.
Toll Free) or 412-317-6671 (International). Participants must use the
following code to access the dial-in replay of the call: 4112552.
About Mytesi®
Mytesi® (crofelemer) is an antidiarrheal indicated for the
symptomatic relief of noninfectious diarrhea in adult patients with
HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not
indicated for the treatment of infectious diarrhea. Rule out infectious
etiologies of diarrhea before starting Mytesi®. If infectious
etiologies are not considered, there is a risk that patients with
infectious etiologies will not receive the appropriate therapy and their
disease may worsen. In clinical studies, the most common adverse
reactions occurring at a rate greater than placebo were upper
respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%),
flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the Amazon rainforest. Napo has
established a sustainable harvesting program for crofelemer to ensure a
high degree of quality and ecological integrity.
About Napo Pharmaceuticals, Inc.
San Francisco-based Napo Pharmaceuticals, Inc. focuses on the
development and commercialization of proprietary pharmaceuticals for the
global marketplace in collaboration with local partners.
For more information, please visit www.napopharma.com.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals, foals, and high value horses.
Canalevia™ is Jaguar’s lead prescription drug product
candidate, intended for the treatment of various forms of diarrhea in
dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s
prescription drug product candidate for the treatment of
gastrointestinal ulcers in horses. Canalevia™ and Equilevia™
contain ingredients isolated and purified from the Croton lechleri
tree, which is sustainably harvested. Neonorm™ Calf and
Neonorm™ Foal are Jaguar’s lead non-prescription products.
Neonorm™ is a standardized botanical extract derived from the Croton
lechleri tree. Canalevia™ and Neonorm™ are
distinct products that act at the same last step in a physiological
pathway generally present in mammals. Jaguar has nine active
investigational new animal drug applications, or INADs, filed with the
FDA and intends to develop species-specific formulations of Neonorm™
in six additional target species, formulations of Equilevia™
in horses, and Canalevia™ for cats and dogs.
For more information about Jaguar, please visit http://www.jaguaranimalhealth.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding the benefits of the
merger between Jaguar and Napo, Jaguar’s intention to develop
species-specific formulations of Neonorm™ in additional
target species, and Jaguar’s plan to develop formulations of Canalevia™
for cats, horses and dogs. In some cases, you can identify
forward-looking statements by terms such as “may,” “will,” “should,”
“expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”
or “continue” or the negative of these terms or other similar
expressions. The forward-looking statements in this release are only
predictions. Jaguar has based these forward-looking statements largely
on its current expectations and projections about future events. These
forward-looking statements speak only as of the date of this release and
are subject to a number of risks, uncertainties and assumptions, some of
which cannot be predicted or quantified and some of which are beyond
Jaguar’s control. Except as required by applicable law, Jaguar does not
plan to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information, future
events, changed circumstances or otherwise.
Jaguar-JAGX
View source version on businesswire.com: http://www.businesswire.com/news/home/20170727006719/en/
Source: Jaguar Animal Health, Inc.
KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
